top of page

X4 Pharma's CEO on the recent launch of XOLREMDI for WHIM Syndrome and CXCR4 inhibition more broadly for additional indications

Jun 7, 2024
1 min read

Paula Ragan describes the launch of this medicine that was approved at the end of April and previews an upcoming data announcement X4 will have in chronic neutropenia towards the end of the month.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page